<DOC>
	<DOCNO>NCT01487720</DOCNO>
	<brief_summary>Prostate cancer one common malignancy affect men World . Metastatic prostate cancer respond androgen deprivation variable period ( 20-25 month ) . Prostate cancer grow despite castrate level testosterone long respond form hormonal manipulation define castrate resistant prostate cancer ( CRPC ) . Docetaxel combine prednisolone show improve QOL PSA response CRPC , also extend overall survival1 . However , efficacy drug universally effective , nearly patient disease progression docetaxel treatment . After failure docetaxel regimen , With exception cabazitaxel abiraterone , widely easily availabe Korea , little treatment regimen apply patient reasonable response benefit . Gemcitabine nucleoside analog activity broad spectrum solid tumor . When gemcitabine use first-line therapy CRPC , disease control rate 33 % median duration 7.1 month . When combined prednisone zoledronic acid pretreated patient CRPC , PSA response rate 23 % disease control rate 57 % patient measurable disease . Oxaliplatin new platinum agent favorable toxicity profile evidence activity cisplatin-resistant cell line . Droz et al . perform multicenter phase II study 54 patient metastatic CRPC randomize receive oxaliplatin either alone 5-FU . More 50 % patient receive prior chemotherapy include cisplatin . Despite heavy pretreatment , PSA desclines note 11 % 19 % patient arm . Gemcitabine plus oxaliplatin combination widely study report safe effective various cancer . This study ass efficacy safety GEMOX docetaxel-refractory CRPC .</brief_summary>
	<brief_title>GEMOX Docetaxel-Refractory Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate Clinical radiologic evidence metastatic disease Documented disease progression hormone therapy ( ADT plus antiandrogen ) response ADT withdrawal Docetaxelrefractory disease define disease progression document either treatment within 60 day cessation treatment docetaxel Prior exposure estramustine mitoxantrone allow KPS â‰¥ 60 No prior radioisotope therapy No prior radiotherapy 25 % bone marrow No peripheral neuropathy grade 2 bad Adequate organ bone marrow function Other tumor type adenocarcinoma Presence history CNS metastasis Other serious illness medical condition</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Castration-resistant prostate cancer</keyword>
	<keyword>Docetaxel-refractory status</keyword>
</DOC>